(DIR) Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
 (HTM) https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
 (DIR) Return to: BRIUMVI (ublituximab)
       *****************************************************
       #Post#: 1839--------------------------------------------------
       Two new MS drugs being developed: umbralisib (TGR-1202), ublitux
       imab (TG-1101)
       By: agate Date: October 3, 2017, 8:14 pm
       ---------------------------------------------------------
       From Multiple Sclerosis News Today (October 3, 2017) comes news
       of two new MS drugs in the pipeline:
 (HTM) https://multiplesclerosisnewstoday.com/2017/10/03/national-ms-society-tg-therapeutics-partner-to-advance-tgr-1202-for-progressive-ms/
 (HTM) https://multiplesclerosisnewstoday.com/2017/10/03/national-ms-society-tg-therapeutics-partner-to-advance-tgr-1202-for-progressive-ms/
       #Post#: 1979--------------------------------------------------
       (ACTRIMS) 6-month results of phase 2a multicenter study of ublit
       uximab in RMS
       By: agate Date: February 7, 2018, 7:59 pm
       ---------------------------------------------------------
       Abstract of a paper on ublituximab presented at the annual
       ACTRIMS (Americas Committee for Treatment and Research in
       Multiple Sclerosis) conference in San Diego, February 1-3, 2018.
       The paper is entitled "6-month results of a Phase 2a multicenter
       study of ublituximab, a novel glycoengineered anti-CD20
       monoclonal antibody, in relapsing multiple
       sclerosis."[center][/center]:
 (HTM) https://actrims.confex.com/actrims/2018/meetingapp.cgi/Paper/2742
       #Post#: 2112--------------------------------------------------
       (CMSC2018) MS patients treated w/ublituximab show benefits in Ph
       ase 2 study
       By: agate Date: June 9, 2018, 8:26 pm
       ---------------------------------------------------------
       From Multiple Sclerosis News Today (June 5, 2018)--"CMSC2018:
       MS Patients Treated with Ublituximab Show Benefits in Phase 2
       Study" (results presented at the Consortium of Multiple
       Sclerosis Centers 2018 conference, May 30 - June 2):
 (HTM) https://multiplesclerosisnewstoday.com/2018/06/05/cmsc2018-phase-2-study-supports-ublituximab-efficacy-in-relapsing-multiple-sclerosis/?utm_source=Multiple+Sclerosis&utm_campaign=6819f167ac-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-6819f167ac-71286581
       *****************************************************